Takeda to Present Late-Stage Oncology Data at ESMO 2026, Highlighting Key Pipeline Progress
Event summary
- Takeda will present late-breaking Phase 3 data on arcotatug tavatecan (TAK-921) for advanced gastric cancer at ESMO 2026.
- New findings for TAK-928 in immunotherapy-resistant and first-line non-small cell lung cancer (NSCLC) will also be featured.
- Real-world data on ALUNBRIG and FRUZAQLA will be shared, highlighting treatment patterns and outcomes.
- Takeda is expanding the MarsLight-11 study to include non-squamous NSCLC patients.
The big picture
Takeda's presentation at ESMO 2026 underscores its strategic focus on advancing therapies for prevalent and challenging cancers. The company's late-stage pipeline, particularly in gastric cancer and NSCLC, reflects its commitment to addressing unmet needs in oncology. The expansion of the MarsLight-11 study and the potential regulatory filing for arcotatug tavatecan highlight Takeda's efforts to strengthen its portfolio in key therapeutic areas.
What we're watching
- Regulatory Pathway
- Whether the Phase 3 G-HOPE-001 study results will support a regulatory filing for arcotatug tavatecan in Japan.
- Clinical Trial Expansion
- The pace at which the MarsLight-11 study enrolls non-squamous NSCLC patients and yields initial data.
- Competitive Positioning
- How Takeda's oncology pipeline progress will position it against competitors in the thoracic and gastrointestinal cancer markets.
Related topics